BRIEF-Oramed Announces Joint Venture To Develop And Commercialize Oral Insulin

Reuters02-11

Feb 11 (Reuters) - Oramed Pharmaceuticals ORMP.O:

ORAMED ANNOUNCES TRANSFORMATIVE JOINT VENTURE TO ACCELERATE DEVELOPMENT AND COMMERCIALIZATION OF ORAL INSULIN
ORAMED PHARMACEUTICALS INC - ANNOUNCES JOINT VENTURE WITH HTIT TO FORM ORATECH
ORAMED PHARMACEUTICALS INC: HTIT TO INVEST $60 MILLION, ORAMED TO INVEST $15 MILLION INTO ORATECH
ORAMED PHARMACEUTICALS INC - NEW PHASE 3 TRIAL IN U.S. EXPECTED TO BEGIN THIS QUARTER
ORAMED PHARMACEUTICALS INC: ORAMED SHAREHOLDERS TO RECEIVE RIGHT TO A DIRECT STAKE IN ORATECH, EXPECTED TO GO PUBLIC ON NASDAQ
ORAMED PHARMACEUTICALS INC - ORATECH TO RECEIVE ROYALTY PAYMENTS FROM SALES OF ORAL INSULIN IN CHINA

Source text: ID:nPn3ZKqvVa

Further company coverage: ORMP.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2510382364?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-02-11 22:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510382364","market":"us","top_or_hot":-1,"title":"BRIEF-Oramed Announces Joint Venture To Develop And Commercialize Oral Insulin","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Oramed Announces Joint Venture To Develop And Commercialize Oral Insulin</title></head><body><p><span>Feb 11 (Reuters)</span><span> - </span>Oramed Pharmaceuticals <span>ORMP.O</span>:</p><ul><li><p>ORAMED ANNOUNCES TRANSFORMATIVE JOINT VENTURE TO ACCELERATE DEVELOPMENT AND COMMERCIALIZATION OF ORAL INSULIN</p></li><li><p>ORAMED PHARMACEUTICALS INC - ANNOUNCES JOINT VENTURE WITH HTIT TO FORM ORATECH</p></li><li><p>ORAMED PHARMACEUTICALS INC: HTIT TO INVEST $60 MILLION, ORAMED TO INVEST $15 MILLION INTO ORATECH</p></li><li><p>ORAMED PHARMACEUTICALS INC - NEW PHASE 3 TRIAL IN U.S. EXPECTED TO BEGIN THIS QUARTER</p></li><li><p>ORAMED PHARMACEUTICALS INC: ORAMED SHAREHOLDERS TO RECEIVE RIGHT TO A DIRECT STAKE IN ORATECH, EXPECTED TO GO PUBLIC ON NASDAQ</p></li><li><p>ORAMED PHARMACEUTICALS INC - ORATECH TO RECEIVE ROYALTY PAYMENTS FROM SALES OF ORAL INSULIN IN CHINA</p></li></ul><p>Source text: <span>ID:nPn3ZKqvVa</span></p><p>Further company coverage: <span>ORMP.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Oramed Announces Joint Venture To Develop And Commercialize Oral Insulin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Oramed Announces Joint Venture To Develop And Commercialize Oral Insulin\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-02-11 22:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Oramed Announces Joint Venture To Develop And Commercialize Oral Insulin</title></head><body><p><span>Feb 11 (Reuters)</span><span> - </span>Oramed Pharmaceuticals <span>ORMP.O</span>:</p><ul><li><p>ORAMED ANNOUNCES TRANSFORMATIVE JOINT VENTURE TO ACCELERATE DEVELOPMENT AND COMMERCIALIZATION OF ORAL INSULIN</p></li><li><p>ORAMED PHARMACEUTICALS INC - ANNOUNCES JOINT VENTURE WITH HTIT TO FORM ORATECH</p></li><li><p>ORAMED PHARMACEUTICALS INC: HTIT TO INVEST $60 MILLION, ORAMED TO INVEST $15 MILLION INTO ORATECH</p></li><li><p>ORAMED PHARMACEUTICALS INC - NEW PHASE 3 TRIAL IN U.S. EXPECTED TO BEGIN THIS QUARTER</p></li><li><p>ORAMED PHARMACEUTICALS INC: ORAMED SHAREHOLDERS TO RECEIVE RIGHT TO A DIRECT STAKE IN ORATECH, EXPECTED TO GO PUBLIC ON NASDAQ</p></li><li><p>ORAMED PHARMACEUTICALS INC - ORATECH TO RECEIVE ROYALTY PAYMENTS FROM SALES OF ORAL INSULIN IN CHINA</p></li></ul><p>Source text: <span>ID:nPn3ZKqvVa</span></p><p>Further company coverage: <span>ORMP.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nTUA3X8XTP:1","article_id":"2510382364","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510382364","pubTimestamp":1739283468,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Oramed Announces Joint Venture To Develop And Commercialize Oral InsulinFeb 11 (Reuters) - Oramed Pharmaceuticals ORMP.O:ORAMED ANNOUNCES TRANSFORMATIVE JOINT VENTURE TO ACCELERATE DEVELOPMENT A","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"简介-Oramed宣布成立合资企业开发和商业化口服胰岛素","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ORMP":0.9},"content_text":"BRIEF-Oramed Announces Joint Venture To Develop And Commercialize Oral InsulinFeb 11 (Reuters) - Oramed Pharmaceuticals ORMP.O:ORAMED ANNOUNCES TRANSFORMATIVE JOINT VENTURE TO ACCELERATE DEVELOPMENT AND COMMERCIALIZATION OF ORAL INSULINORAMED PHARMACEUTICALS INC - ANNOUNCES JOINT VENTURE WITH HTIT TO FORM ORATECHORAMED PHARMACEUTICALS INC: HTIT TO INVEST $60 MILLION, ORAMED TO INVEST $15 MILLION INTO ORATECHORAMED PHARMACEUTICALS INC - NEW PHASE 3 TRIAL IN U.S. EXPECTED TO BEGIN THIS QUARTERORAMED PHARMACEUTICALS INC: ORAMED SHAREHOLDERS TO RECEIVE RIGHT TO A DIRECT STAKE IN ORATECH, EXPECTED TO GO PUBLIC ON NASDAQORAMED PHARMACEUTICALS INC - ORATECH TO RECEIVE ROYALTY PAYMENTS FROM SALES OF ORAL INSULIN IN CHINASource text: ID:nPn3ZKqvVaFurther company coverage: ORMP.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2510382364"}